Abstract
The discovery and characterization of natural congeners is one approach for understanding the relationship between chemical structure and biological function. We recently isolated the novel antifungal metabolite KB425796-A produced by the recently isolated bacterium Paenibacillus sp. 530603. On the basis of morphological changes of Aspergillus fumigatus induced by KB425796-A in combination with micafungin, we developed a highly sensitive screening method for the specific detection of KB425796-A congeners. Using this method, we isolated ten congeners of KB425796-A, named KB425796-B, -C, -D, -E, -F, -G, -H, -I, -J and -K, which exhibited diverse antifungal potencies against A. fumigatus. One of the most potent congeners, KB425796-C, had antifungal activities against several micafungin-resistant infectious fungi. KB425796-C can be a potential drug candidate for treating micafungin-resistant fungal infections.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R. & Walsh, T. J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. 45, 3310–3321 (2001).
Clemons, K. V. & Stevens, D. A. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med. Mycol. 44, 69–73 (2006).
Kato, A. et al. A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities. J. Antibiot. 51, 929–935 (1998).
Fujie, A. et al. FR901469, a novel antifungal antibiotic from an unidentified fungus No.11243. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological properties. J. Antibiot. 53, 912–919 (2000).
Fujie, A. et al. FR901469, a novel antifungal antibiotic from an unidentified fungus No.11243. II. In vitro and in vivo activities. J. Antibiot. 53, 920–927 (2000).
Tawara, S. et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44, 57–62 (2000).
Debono, M. & Gordee, R. S. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48, 471–497 (1994).
Liu, J. & Balasubramanian, M. K. 1,3-beta-Glucan synthase: a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 1, 159–169 (2001).
Kai, H. et al. KB425796-A, a novel antifungal antibiotic produced by Paenibacillus sp. 530603. J. Antibiot. 66, 465–471 (2013).
Matsubara, H. & Sasaki, R. M. High recovery of tryptophan from acid hydrolysates of proteins. Biochem. Biophys. Res. Commun. 35, 175–181 (1969).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kai, H., Yamashita, M., Takase, S. et al. Identification of ten KB425796-A congeners from Paenibacillus sp. 530603 using an antifungal assay against Aspergillus fumigatus in combination with micafungin. J Antibiot 66, 473–478 (2013). https://doi.org/10.1038/ja.2013.64
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2013.64
